EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment

Luis Gutiérrez-Rojas iD, Julia Vendrell-Serres, J Antoni Ramos-Quiroga, Jon Iñaki Etxeandia-Pradera, Eduardo Aguilar, Ana Isabel De Santiago-Díaz, Daniel Hernández-Huerta iD, Vicente Tordera, Carlos Vázquez-Ventoso, Moisés Bolívar, Asunción Abril, Rubén Catalán-Barragán und 1 weitere

Journal of Psychopharmacology · 2025

DOI: 10.1177/02698811241267837 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Psychopharmacology, 2025. Verfasst von Luis Gutiérrez-Rojas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain. Hauptthemen laut MEDLINE: Depressive Disorder, Treatment-Resistant, Ketamine, Major Depressive Disorder, Antidepressive Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Treatment-resistant depression (TRD) is defined as the failure of at least two antidepressants in adequate doses and timing during a major depressive episode. Esketamine intranasal (ESK-IN) has been approved by the Food and Drug Administration and the European Medicines Agency for the treatment of TRD in combination with other antidepressants.

Aims

To assess the effectiveness and tolerability of a sample of TRD patients who received treatment with ESK-IN as part of the compassionate use program.

Methods

A retrospective, observational study was carried out on patients with a diagnosis of TRD enrolled in the early access program of ESK-IN in nine centers. Effectiveness was assessed with the Montgomery-Asberg depression rating scale (MADRS) at four time points: baseline, 28, 90, and 180 days of treatment.

Results

The sample included 71 patients (70% women) with a mean baseline MADRS score of 38.27 ± 5.9 and total or partial work disability rates of 85%. ESK-IN treatment was associated with a statistically and clinically significant reduction in the severity of depressive symptoms at all time points assessed. The presence of side effects was common but the majority were mild in severity and resolved after the observation period. Those patients who received psychotherapy in combination with ESK-IN showed a significantly lower MADRS score at 90 and 180 days than those patients who did not undergo psychotherapy.

Conclusion

ESK-IN has proven to be effective and safe in a clinical sample of patients with severe TRD. To optimize clinical outcomes, the pharmacological treatment for TRD should always be integrated into a comprehensive therapeutic plan that encompasses strategies such as psychotherapy, social support, and family interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Depressive Disorder, Treatment-ResistantKetamineMajor Depressive DisorderAntidepressive AgentsHumansMaleFemaleAdministration, IntranasalMiddle AgedAdultRetrospective StudiesCompassionate Use TrialsTreatment OutcomeSeverity of Illness IndexPsychiatric Status Rating Scales

Stichwörter der Autor:innen

Intranasal esketaminecompassionate usefunctional impairmentpsychotherapytreatment-resistant depression

Substanzen

EsketamineKetamineAntidepressive Agents

Autor:innen und Institutionen

  • Department of Psychiatry and Neurosciences Research Group (CTS-549), Institute of Neurosciences, University of Granada, Granada, Spain.
  • Psychiatry Service, Hospital Clínico San Cecilio, Granada, Spain.
  • Department of Mental Health, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Group of Psychiatry, Mental Health and Addictions, Vall d'Hebron Research Institute, Barcelona, Spain.
  • Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona, Spain.

ORCID-Profile: Luis Gutiérrez-Rojas, Daniel Hernández-Huerta

Zitieren

APA

Gutiérrez-Rojas, L., Vendrell-Serres, J., Ramos-Quiroga, J. A., Etxeandia-Pradera, J. I., Aguilar, E., De Santiago-Díaz, A. I., Hernández-Huerta, D., Tordera, V., Vázquez-Ventoso, C., Bolívar, M., Abril, A., Catalán-Barragán, R., & García-Jiménez, J. (2025). Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment. Journal of Psychopharmacology. https://doi.org/10.1177/02698811241267837

Vancouver

Gutiérrez-Rojas L, Vendrell-Serres J, Ramos-Quiroga JA, Etxeandia-Pradera JI, Aguilar E, De Santiago-Díaz AI, et al. Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment. Journal of Psychopharmacology. 2025. doi:10.1177/02698811241267837

BibTeX
@article{GutirrezRojas2025,
  author = {Gutiérrez-Rojas, Luis and Vendrell-Serres, Julia and Ramos-Quiroga, J Antoni and Etxeandia-Pradera, Jon Iñaki and Aguilar, Eduardo and De Santiago-Díaz, Ana Isabel and Hernández-Huerta, Daniel and Tordera, Vicente and Vázquez-Ventoso, Carlos and Bolívar, Moisés and Abril, Asunción and Catalán-Barragán, Rubén and García-Jiménez, Jesús},
  title = {Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment},
  journal = {Journal of Psychopharmacology},
  year = {2025},
  doi = {10.1177/02698811241267837}
}
Kostenlos starten →